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Edited by Lukas HuberAbstract Cyclophosphamide (CPA) is one of the therapeutic
agents for systemic inﬂammatory disorders. In murine dermal
endothelial cells (F-2), 4-hydroxycyclophosphamide (4-HC),
which is active metabolite of CPA, enhanced TNF-a-induced
DNA fragmentation. In addition, 4-HC was shown to elevate
TNF-a-induced caspase-3 activation. Caspase-8 activation was
identiﬁed by the treatment of TNF-a, whereas 4-HC was no
eﬀect. In contrast, only when treated with 4-HC, caspase-9
activation and the increase in the intracellular expression of
Bax were detected. These results suggest that CPA may sensitize
endothelial cells to TNF-a-induced apoptosis through a mito-
chondria-dependent pathway and clinically may contribute to
the limitation of inﬂammatory process.
 2006 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Caspase; Bax1. Introduction
Apoptosis is an essential event for tissue homeostasis and it
is tightly regulated at the molecular level. Two main pathways
to apoptotic cells have been identiﬁed; the one is the interac-
tion of a death receptor and the other is the participation of
mitochondria. Pro-apoptotic and anti-apoptotic members of
the Bcl-2 family regulate mitochondrial pathway. Either path-
way results in the activation of caspase and the cleavage of spe-
ciﬁc cellular substrate [1].
Endothelial cells are activated by cytokines, such as TNF-a,
and play a key role in the inﬂammatory process of various
immunomediated disease [2]. So, the regulation of activated
endothelial cells by some agent may lead to prevent inﬂamma-
tory reactions.
Cyclophosphamide (CPA), which is a widely used anti-can-
cer prodrug, is eﬀective for autoimmune diseases and systemic
vasculitis [3]. It has been shown that CPA suppresses B-cell
function with decreased antibody production [4]. However,
the mechanism of action to endothelial cell is still not eluci-
dated fully. In the present study, we investigated whether 4-
hydroxycyclophosphamide (4-HC), which is active metabolite*Corresponding author. Fax: +81 73 448 1908.
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doi:10.1016/j.febslet.2006.01.092of CPA, might evoke apoptosis in dermal endothelial cells.
We could demonstrate that 4-HC, at therapeutic concentra-
tions, induced apoptosis, and enhanced TNF-a-induced apop-
tosis. Our data suggested that, at least in part, the anti-
inﬂammatory eﬀects of CPA were mediated by the induction
of apoptosis of endothelial cells.2. Materials and methods
2.1. Cell culture and reagents
The murine dermal endothelial cell clone (F-2) was previously estab-
lished [5]. PAM 212 and NIH-3T3 were kindly gifts from Dr. Norihisa
Matsuyoshi (Kyoto University, Kyoto, Japan). These cells were main-
tained in Dulbecco’s modiﬁed Eagle medium (DMEM) supplemented
with 5% fetal bovine serum (FBS) at 37 C under 5% CO2 in air.
4-Hydroxycyclophosphamide (4-HC) was generously provided by
Shionogi Seiyaku Co. Ltd. (Tokyo, Japan). Recombinant murine
TNF-a was purchased from R&D Systems (Minneapolis, MN, USA).
[4-{3-(4-lodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio}-1,3 benzene
disulfonate] (WST-1) was obtained from Roche (Tokyo, Japan). Poly
[ADP-ribose] polymerase (PARP) antibody was from Sigma (Tokyo,
Japan). Polyclonal rabbit anti-mouse Bax was from Santa Cruz Bio-
technology (Santa Cruz, CA, USA). The caspase inhibitors
Z-DEVD-FMK were from MBL (Nagoya, Japan).
2.2. Cell viability assay
Cells (0.5 · 104 cells per well) were grown in 96-well plates (Falcon
Labware, oxnard, CA, USA) with 4-HC at 10 lM or the same amount
of distilled water as vehicle. After 24 h, WST-1 was added to each well.
Then, cells were incubated for 1 h and absorbance was measured with
a microplate reader (Bio-Rad, Tokyo, Japan) at 450 nm, with a refer-
ence wavelength of 630 nm. All assays were run in triplicate.
2.3. DNA agarose gel electrophoresis
Cells (1 · 105 cells) were incubated in 10 cm dishes with 4-HC
(10 lM) or vehicle. After 24 h, the genomic DNA was extracted using
a QIAamp DNAMini Kit (QIAGEN, Tokyo, Japan) and was electro-
phoresed on 2% agarose gel electrophoresis and visualized by ethidium
bromide staining.
2.4. Sandwich ELISA for histone-associated DNA fragments
Cell death was assessed using a cell death detection kit (Roche). Cells
were incubated for 2 h in 96-well plate in the presence or absence of
TNF-a (50 ng/ml) and then cultured with 4-HC (10 lM) or vehicle
for 24 h. The cells were harvested in lysis buﬀer and the cytoplasmic
and nuclear fractions were separated by centrifugation at 200 · g.
The supernatant (cytoplasmic) fraction was added to streptavidine-
coated microtiter plate, followed by biotin-labeled anti-histone anti-
body and HRP-conjugated anti-DNA antibody. After 2 h, immune
complex was detected using substrate (2,200-azino-di[3-ethyl-benzthiaz-
olin-sulfonate]) for 10 min and absorbance was measured at 405 nm,
with a reference wavelength of 490 nm.ation of European Biochemical Societies.
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Fig. 1. Eﬀects of 4-HC on cell survival in F-2, PAM212, and NIH-
3T3. F-2, PAM212, and NIH-3T3 were grown with 4-HC (10 lM) or
vehicle for 24 h and the number of viable cells was estimated by WST-1
assay. The data are presented as means ± S.D. from three independent
experiments. **P < 0.01.
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Cytosolic extracts were prepared and assayed for caspase activities
according to the manufacture’s protocol (MBL). In brief, cells were
collected and lysed in an ice-cold lysis buﬀer. The cell lysate was cen-
trifuged 10000 · g for 1 min at 4 C and the supernatant fraction
was used. The protein concentration was determined using protein
assay ESL (Roche). Aliquots of 100 lg of protein were incubated with
0.2 mMDEVD-pNA, IETD-pNA, or LEHD-pNA substrate for 2 h at
37 C in reaction buﬀer. The reaction was measured with spectropho-
tometer (Hitachi, Tokyo, Japan) at a wavelength of 405 nm. Fold
increase was calculated by comparing with control.
2.6. Caspase inhibitory assay
Cells were treated with Z-DEVD-FMK for 2 h at 10 lM. Dimethyl
sulfoxide (DMSO) was used as a diluent control. Then, cells were incu-
bated for 2 h in 96-well plate in the presence or absence of TNF-a
(50 ng/ml) and then cultured with 4-HC (10 lM) or vehicle for 24 h.
2.7. Western blot analysis
Cells were harvested in an ice-cold lysis buﬀer containing 20 mM
HEPES (pH7.4), 2 mM EDTA, 250 mM NaCl, 0.1% Nonident P-40,
2 lg/ml leupeptin, 2 lg/ml aprotinin, 1 mM PMSF, 0.5 lg/ml benzam-
idine, 1 mM DTT. Insoluble material was removed by 10000 · g for
5 min at 4 C. Lysates were boiled in sample buﬀer for 5 min. Samples
containing equal amounts of protein (50 lg) were separated by 10%
SDS–PAGE and transferred to nitrocellulose membrane. The mem-
brane was blocked for 1 h with 5% non-fat dried milk in TBS contain-
ing 0.1% Tween 20 (TBS-T). After incubation for 1 h with anti-PARP
antibody or anti-Bax antibody diluted 1:5000 in TBS-T, membranes
were washed three times with TBS-T. The secondary antibody was
incubated at 1:20000 dilution for 1 h. Following three washes with
TBS-T, the protein bands were visualized with ECL system (Amer-
sham Pharmacia Biotech).
2.8. Statistical analysis
Each experiment was performed at least three times and statistical
analysis was performed using the two-tailed Students’ t test.Fig. 2. DNA ladder formation in F-2 treated with 4-HC (10 lM).
DNA was fractionated by 2% agarose gel electrophoresis and
visualized by ethidium bromide staining.3. Results
3.1. 4-Hydroxycyclophosphamide (4-HC) induced apoptotic cell
death in F-2 cells
The growth inhibitory eﬀect of 4-HC was investigated by
WST-1 assay. As shown in Fig. 1, 4-HC at concentration of
10 lM was able to decrease murine endothelial cell (F-2) via-
bility. In keratinocyte (PAM212) and ﬁbroblast (NIH-3T3),
4-HC was no eﬀect at the same concentration. To determine
whether 4-HC can induce endothelial apoptosis, DNA ladder
assay was performed. DNA laddering was observed in cells
treated with 4-HC at concentration of 10 lM (Fig. 2).3.2. 4-HC enhanced TNF-a-induced DNA fragmentation,
caspase-3 activation, and cleavage of PARP
The sandwich ELISA that can detect the enrichment of
mono- or oligo-nucleosomes in cytoplasms of apoptotic cells
was carried out for the purpose of measuring apoptotic cell
death quantitatively. The stimulation with TNF-a (50 ng/ml)
or 4-HC (10 lM) showed higher optical absorbance indepen-
dently in comparison with no stimulation, whereas TNF-a
(50 ng/ml) and 4-HC (10 lM) have additional eﬀect (Fig. 3).
Next, we examined whether caspase-3 contributed to the apop-
tosis. While DEVDase activation was induced by TNF-a
(50 ng/ml) alone, it was enhanced by the combination of 4-
HC (10 lM) and TNF-a (50 ng/ml) (Table 1). In addition,
we measured the cleavage of PARP which is a caspase-3 sub-
strate by Western blot analysis. The expression of the cleavedsubunit of PARP was upregulated in the cells treated with the
combination of TNF-a (50 ng/ml) and 4-HC (10 lM) com-
pared with TNF-a (50 ng/ml) alone (Fig. 4).
3.3. Caspase-3 inhibitor attenuated TNF-a and/or 4-HC-induced
apoptosis
To further investigate the involvement of caspase-3 on TNF-
a and/or 4-HC-induced apoptosis, we determined whether
these apoptosis could be inhibited by caspase-3 inhibitor.
TNF-a (50 ng/ml) and/or 4-HC (10 lM)-induced apoptosis
was signiﬁcantly attenuated by treatments with caspase-3
inhibitor (Fig. 5). These results also suggested that the apopto-
sis were mediated by the activation of caspase-3.
Table 1
Caspase-3 like protease (DEVDase) activation in F-2
TNF-a (50 ng/ml) 4-HC (10 lM)
Caspase-3 activity
(fold increase)
1.81 ± 0.17* 2.84 ± 0.13**
F-2 were incubated for 2 h with TNF-a (50 ng/ml), followed by 4-HC
(10 lM) or vehicle for 24 h. Hydrolysis of DEVD-pNA substrate was
measured at 405 nm. The data are means ± S.D. of three independent
experiments.
*P < 0.05 vs. control.
**P < 0.01 vs. control.
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Fig. 4. Eﬀects of TNF-a with or without 4-HC on the expression of
the cleaved subunit of PARP in F-2. F-2 were incubated for 2 h in the
presence of TNF-a (50 ng/ml) and then cultured with 4-HC (10 lM) or
vehicle for 24 h. The cell lysates were analyzed by Western blotting
with antibody to PARP.
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Fig. 5. Eﬀects of caspase-3 inhibitors on TNF-a and/or 4-HC-induced
apoptosis in F-2. F-2 were pretreated with Z-DEVD-FMK (10 lM) for
2 h and incubated for 2 h in the presence or the absence of TNF-a
(50 ng/ml), followed by 4-HC (10 lM) or vehicle for 24 h. The data are
presented as means ± S.D. from three independent experiments.
*P < 0.05.
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Fig. 3. Eﬀects of TNF-a and 4-HC on DNA fragmentation in F-2. F-2
were incubated for 2 h in the presence or absence of TNF-a (50 ng/ml)
and then cultured with 4-HC (10 lM) or vehicle for 24 h. The
sandwich ELISA that can detect the enrichment of mono- or oligo-
nucleosomes in cytoplasms of apoptotic cells was carried out as
described in Section 2. The data are presented as means ± S.D. from
three independent experiments. *P < 0.05, **P < 0.01.
Table 2
Caspase-8 like protease (IETDase) or caspase-9 like protease (LHE-
Dase) activation in F-2
TNF-a (50 ng/ml) 4-HC (10 lM)
Caspase-8 activity (fold increase) 1.74 ± 0.30* 1.25 ± 0.22
Caspase-9 activity (fold increase) 1.27 ± 0.17 1.88 ± 0.36*
F-2 were incubated for 24 h with TNF-a (50 ng/ml)or 4-HC (10 lM).
Hydrolysis of IETD-pNA or LHED-pNA substrate was measured at
405 nm. The data are means ± S.D. of three independent experiments.
*P < 0.05 vs. control.
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Fig. 6. Eﬀects of TNF-a or 4-HC on the expression of Bax in F-2. F-2
were incubated with TNF-a (50 ng/ml)or 4-HC (10 lM) for 24 h. The
cell lysates were analyzed by Western blotting with antibody to Bax.
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of TNF-a, whereas the activation of caspase-9 was by 4-HC
We next examined whether ‘‘upstream’’ caspases such as cas-
pase-8 and caspase-9 contributed to the apoptosis. IETDase
activation was induced by TNF-a (50 ng/ml), but not by 4-
HC (10 lM). In contrast, LEHDase activation was induced
by 4-HC (10 lM), but not by TNF-a (50 ng/ml) (Table 2).
3.5. The intracellular expression of pro-apoptotic protein Bax
was increased by the treatment of 4-HC
Further, we examined the expression levels of Bax, which is
the major pro-apoptotic Bcl-2 protein, by Western blot analy-
sis. Expression of Bax in the cells treated with TNF-a (50 ng/
ml) was similar to the cells untreated, whereas it was elevated
in the cells treated with 4-HC (Fig. 6).4. Discussion
In our experiment, 4-HC (10 lM) inhibited the viability of
murine dermal endothelial cells (F-2), whereas it did not exhi-
bit signiﬁcant eﬀect on the viability of keratinocyte (PAM212)
and ﬁbroblast (NIH-3T3). The concentration used in this
study in vitro, are equivalent to the physiological concentra-
tion after treatment of CPA in vivo [6]. Consistent with a re-
cent report [7], these results demonstrated that endothelial
cells were more susceptible to the eﬀects of CPA than other
cells. In addition, it was suggested that the inhibitions of cell
viability were involved in apoptosis using DNA ladder assay
and the cell death detection ELISA.
As the release of TNF-a is supposed to be elevated at inﬂam-
matory site, the ELISA assay was performed to clarify the
1600 T. Ohtani et al. / FEBS Letters 580 (2006) 1597–1600eﬀect of 4-HC after TNF-a stimulation. The treatment with
TNF-a (50 ng/ml) or 4-HC (10 lM) showed higher optical
absorbance independently than no treatment, whereas TNF-
a (50 ng/ml) and 4-HC (10 lM) have additional eﬀect.
Although it was reported that the stimulation with TNF-a
alone did not induce DNA fragmentation of human umbilical
vein endothelial cells (HUVEC) [8], our result indicated that
TNF-a alone induced DNA fragmentation of F-2. The mech-
anisms of the diﬀerential sensitivity to TNF-a between HU-
VEC and F-2 is not currently unknown. However, one likely
possibility is due to the expression pattern of anti-apoptotic
proteins after TNF-a stimulation [9–11].
Recently, glucocorticoid was shown to suppress TNF-a-in-
duced apoptosis in glomerular endothelial cells [12]. Indeed,
this report is in accordance with our result that prednisolone
inhibit TNF-a-induced DNA fragmentation in F-2 (data not
shown). Although glucocorticoid is also eﬀective for autoim-
mune diseases and systemic vasculitis [13], it is possible that
the mechanism to endothelial cell is diﬀerent from CPA.
Caspase-3 has been shown to play a pivotal role as a down-
stream member of the protease cascade, and several proteins
were identiﬁed as caspase-3 substrates, such as PARP [14]. It
was clariﬁed that the treatment of 4-HC (10 lM) enhanced
TNF-a (50 ng/ml)-induced caspase-3 like protease (DEVDase)
activity and upregulated the expression of the cleaved subunit
of PARP. Furthermore, TNF-a (50 ng/ml) and/or 4-HC
(10 lM)-induced apoptosis of F-2 was signiﬁcantly attenuated
by treatments with caspase-3 inhibitor. These ﬁndings con-
ﬁrmed that caspase-3 activation was involved in the apoptosis
induced by these reagents.
In an attempt to characterize the pathway, upstream of cas-
pase-3, responsible for TNF-a or 4-HC-induced apoptosis of
F-2, the activities of caspase-8 and caspase-9 were next inves-
tigated. Caspase-8 plays a important role in TNF-a-induced
apoptosis by activating caspase-3 directly [15] or by triggering
cytochrome c release from mitochondria through cleaved Bid,
a pro-apoptotic Bcl-2 family member [16]. The cytochrome c
binds to Apaf-1 and activates caspase-9, which in turn cleaves
and activates caspase-3. In TNF-a-induced apoptosis of F-2,
induction of caspase-8 like protease (IETDase) activity was
observed, whereas caspase-9 like protease (LEHDase) activity
was not changed. Then, it was suggested that main pathway of
TNF-a induced apoptosis in F-2 was mitochondria-indepen-
dent. In contrast, induction of caspase-9 like protease (IEH-
Dase) activity was observed in 4-HC-induced apoptosis.
CPA was reported to induce caspase-9 dependent apoptosis
in other cells as well [17].
We further investigated the expression levels of Bax, one of
the pro-apoptotic proteins, which plays a major role in initiat-
ing cytochrome c release [18]. We found that the expression
was elevated in the cells treated with 4-HC, although the
expression of Bcl-2 and Bcl-XL, the anti-apoptotic proteins,
which work to prevent Bax, thereby preserving cell survival,
was not changed (data not shown).
In conclusion, we propose that there are diﬀerent pathways
to apoptotic cells, upstream of caspase-3, for TNF-a and CPA
in murine vascular endothelial cells. If, as a result, CPA could
easily induce the apoptosis of activated endothelial cells, it may
be a suitable mechanism to limit inﬂammatory process. Our
observations will provide new implications into the anti-
inﬂammatory eﬀects of CPA.Acknowledgement: This work was supported by the grant from Funds
for Research on Refractory Vasculitis of the Ministry of Health, Labor
and Welfare and Segawa Research Grant.References
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